Phase 3 Decompensated Heart Failure Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Acute Decompensated Heart Failure (ADHF)
Christian Schulze536 enrolled9 locationsNCT07038356
Recruiting
Phase 3
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Acute Decompensated Heart Failure
Reprieve Cardiovascular, Inc400 enrolled53 locationsNCT06898515
Recruiting
Phase 3
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Acute Decompensated Heart Failure
Helwan University60 enrolled1 locationNCT06535529
Terminated
Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency
Acute Decompensated Heart Failure
Biogen Idec Pty Ltd65 enrolled19 locationsACTRN12608000607370